Online inquiry

IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4240MR)

This product GTTS-WQ4240MR is a type of mRNA modified with 5-Methyl-CTP & Pseudo-UTP, which ecodes the monoclonal antibody that targets Factor VIII substitute gene. The antibody can be applied in Hemophilia A research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000132.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2157
UniProt ID P00451
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4240MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3593MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ13684MR IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RC18
GTTS-WQ6914MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ENB-0040
GTTS-WQ10222MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LFB-R593
GTTS-WQ9018MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ254MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 17-1A
GTTS-WQ1494MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ1009MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-383
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW